How does the POSEIDON meta-analysis results influence your decision on which patients should receive hormone therapy with post-operative radiotherapy for recurrent prostate cancer?
Community PollStarted
In patients receiving salvage radiotherapy after radical prostatectomy without radiographic evidence of recurrence and PSA 0.2–0.5, how do you typically incorporate androgen deprivation therapy?
372 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center
Answered on
POSEIDON is another landmark analysis from the MARCAP consortium. It adds to the seminal work performed in localized prostate cancer (Kishan et al., PMID 35051385), which serves as the reference study for the use and duration of ADT with radiotherapy, but now in the post-prostatectomy setting.
The st...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · SUNY Upstate Medical University
Answered on
While I may be in the minority, I am happy to play devil's advocate:
While POSEIDON is instructive and provocative, I believe that RTOG 0534 (SPPORT) is the highest quality phase III data that we have, and I currently use this data (~1,800 patients) to help guide discussions with patients.
RTOG 0534 u...
Join for free or sign in to see the full answer